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ABSTRACT
Background: A single-arm phase II study of neoadjuvant chemotherapy plus durvalumab 
and tremelimumab in the treatment of advanced-stage ovarian cancer has begun in Korea. 
We hypothesized that adding durvalumab (anti-programmed death-ligand 1 antibody) and 
tremelimumab (anti-cytotoxic T-lymphocyte-associated protein 4 antibody) to chemotherapy in 
treating this cancer can increase progression-free survival (PFS) with minimal effects on safety.
Methods: During treatment, serial biopsies will be performed on pre-treatment, at interval 
debulking surgery and progression to identify immune biomarkers and changes in the 
tumor microenvironment. Patients with histologically confirmed stage IIIC/IV epithelial 
ovarian cancer are offered durvalumab, tremelimumab plus chemotherapy for neoadjuvant 
chemotherapy and durvalumab plus chemotherapy for adjuvant chemotherapy. Twenty-four 
patients will be included from four Korean institutions within 1 year. The primary endpoint is 
a 12-month PFS rate.
Trial Registration: ClinicalTrials.gov Identifier: NCT03899610
Keywords: Epithelial Ovarian Cancer; Chemotherapy; Durvalumab; Tremelimumab; 
Immunotherapy
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INTRODUCTION
Ovarian cancer is the deadliest gynecological cancer in Korea [1]. The standard therapy is 
surgical cytoreduction followed by taxane-platinum combination chemotherapy. Several 
phase 3 clinical trials have demonstrated that survival, postoperative morbidity, and mortality 
rates after neoadjuvant chemotherapy followed by interval debulking surgery are no worse 
than those after primary debulking surgery in patients with stages III–IV ovarian cancer [2-4]. 
Therefore, neoadjuvant chemotherapy followed by interval debulking surgery is an alternative 
option for patients with unresectable high tumor burden. Most patients with advanced-stage 
ovarian cancer will achieve complete or partial remission after standard-of-care treatment 
but eventually will have a relapse. Recent randomized phase 3 studies showed median 
progression-free survival (PFS) was only 12 months with current chemotherapy in stages III/
IV disease [2,4]. Therefore, there is an urgent need to improve the outcomes of patients with 
this aggressive cancer.
Some recent clinical trials have studied the addition of immune-oncology drugs to 
current chemotherapy as a front-line treatment. Researchers have especially studied to 
determine the optimal approach to using immune checkpoint inhibitors. Most strategies 
considered in front-line settings have been combinations of anti-programmed cell death 
protein 1 (PD-1) or anti-programmed death-ligand 1 (PD-L1) inhibitors and chemotherapy. 
IMagyn050 (NCT00262847) is a phase III randomized study designed to compare 
the efficacy and safety of atezolizumab+paclitaxel+carboplatin+bevacizumab versus 
placebo+paclitaxel+carboplatin+bevacizumab in 1,300 ovarian cancer patients [5]. JAVELIN 
OVARIAN 100 (NCT02718417) is a phase III randomized study investigating avelumab in 
combination with and/or as a maintenance treatment after a regime of carboplatin/paclitaxel 
chemotherapy in treating 998 ovarian cancer patients. However, when used as part of a planned 
interim analysis, JAVELIN OVARIAN 100 does not permit having a primary endpoint for PFS.
So far, emerging clinical data shows a limited clinical efficacy of immune checkpoint 
inhibitors in ovarian cancer; the results have been objective response rates (ORRs) of 
10%–15%, with some durable responses. Because ovarian cancer is an immunologically 
cold tumor [6], the use of PD-1 or PD-L1 inhibitors alone likely will have limited benefit. We 
suggest combination therapy to turn cold tumor into hot tumor. To improve the efficacy of 
a PD-L1 inhibitor, a combination of a cytotoxic T-lymphocyte-associated protein 4 (CTLA-
4) inhibitor and chemotherapy has been suggested with promising prospects. NRG GY003 
showed that combining nivolumab and ipilmumab was more effective than nivolumab alone 
(ORR: 31.4% vs. 12.2%) in recurrent ovarian cancer. Korean Gynecologic Oncology Group 
(KGOG) 3045 is an umbrella study of biomarker-driven targeted therapy in patients with 
platinum-resistant recurrent ovarian cancer. In this study, one of treatment arms includes 
durvalumab and tremelimumab plus nonplatinum-based standard of chemotherapy (SOC) 
(weekly palictaxel, topotecan, or liposomal doxorubicin). In other solid cancers, several 
ongoing studies such as POSEIDON continue to evaluate the efficacy and safety of the anti-
PD-L1 and anti-CTLA-4 antibodies plus chemotherapy. In addition, some chemotherapeutic 
agents induce immunogenic cells and potentially improve the efficacy of immune 
checkpoint inhibitors [7]. Therefore, we proposed a combination therapy of durvalumab, 
tremelimumab, and chemotherapy to improve outcomes in advanced-stage ovarian cancer. 
KGOG 3046 will be uniquely positioned to elucidate whether dual checkpoint inhibition 
(durvalumab+tremelimumab) with chemotherapy can improve survival without excess 
toxicity for patients.
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This study protocol was approved by AstraZeneca in June 2018 and the Scientific Review Board 
of the KGOG in October 2018. Patient enrollment began in June 2019. We obtained approval 
from the Institutional Review Board before initiating patient accrual at each institution (4-2019-
0083). This trial has been registered with ClinicalTrials.gov NCT03699449.
PROTOCOL OF THE KGOG 3046 STUDY
1. Objective
This single-arm phase II study aims to explore the synergistic effects of durvalumab and 
tremelimumab plus chemotherapy in advanced-stage ovarian cancer.
The secondary objective is to explore the safety of durvalumab and tremelimumab plus 
chemotherapy in advanced-stage ovarian cancer.
An exploratory objective is to identify changes in immune biomarkers by comparing tissue 
and blood samples before and after treatment.
2. Endpoints
The primary endpoint of the study is a 12-months PFS rate.
The secondary endpoints include response rates by Response Evaluation Criteria in Solid 
Tumors version 1.1 after neoadjuvant chemotherapy, immune-related response criteria after 
neoadjuvant chemotherapy, response rates by PET Response Criteria in Solid Tumors after 
neoadjuvant chemotherapy, R0 rate at interval debulking surgery, the rate of chemotherapy 
response scores (CRS) of 3 at interval debulking surgery, overall survival (OS), safety, and 
duration of response.
PFS is defined as the time from the start of treatment until the first documented sign of 
disease progression or death from any cause; OS is defined as the time from first treatment 
until death from any cause. We will estimate PFS and OS using Kaplan-Meier techniques and 
calculate 95% confidence intervals.
The following are the details of how (CRS) will be analyzed. An experienced gynecologic 
pathologist (Prof. Hyun Soo Kim and Sang Yong Song) will score each slide independently 
according to the 3-tiered CRS system proposed by Bohm et al. Resected specimens from 
interval debulking surgery will be formalin-fixed and paraffin-embedded according to 
standard procedures and stained with hematoxylin and eosin stain. The slide with the most 
viable tumor and/or the least chemotherapy response will be selected from the omentum.
3. Study design
Single arm, phase II study.
ELIGIBILITY CRITERIA
1. Inclusion criteria
1) Histologically confirmed adenocarcinoma of ovary, fallopian tube, primary peritoneum 
(non-mucinous).
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2) Clinical stages IIIC/IV.
3) Eastern Cooperative Oncology Group performance status of 0–1.
4) Females aged 20 years or older at the time of acquisition of informed consent.
5) Adequate organ function.
6) Body weight >30 kg.
2. Exclusion criteria
1) A serious concomitant systemic disorder that, in the opinion of the investigator, would 
compromise the patient's ability to complete the study.
2) Patients with active or uncontrolled infections or with serious illnesses or medical 
conditions.
3) Active pulmonary tuberculosis.
4) Known acute or chronic hepatitis B or C by serological evaluation.
5) Known human immunodeficiency virus infection.
6) History of another primary malignancy that is currently clinically significant or currently 
requires active intervention.
7) Inability to comply with protocol or study procedures.
RANDOMIZATION
Not applicable.
TREATMENT
Patients with histologically confirmed ovarian cancer are offered durvalumab, tremelimumab 
plus chemotherapy. KGOG 3046 regimen consists of 21-day cycles with durvalumab, 
tremelimumab plus chemotherapy for neoadjuvant chemotherapy and durvalumab plus 
chemotherapy for adjuvant chemotherapy (Fig. 1).
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Biopsy
Pre-treatment: Biopsy #1
Fresh frozen
Immune marker analysis using FACS
PD-L1 expression (SP263)
Exome sequencing
RNA sequencing
Surgical specimen: Biopsy #2
Fresh frozen
Immune marker analysis using FACS
PD-L1 expression (SP263)
Exome sequencing
RNA sequencing
Post-treatment: Biopsy #3
Fresh frozen (optional)
Immune marker analysis using FACS
PD-L1 expression (SP263)
Exome sequencing
RNA sequencing
Biopsy
Interval
debulking
surgery
Neoadjuvant chemotherapy
Paclitaxel-carboplatin Q3W
Tremelimumab 75 mg Q3W
Durvalumab 1,500 mg Q3W
Adjuvant chemotherapy
Paclitaxel-carboplatin Q3W
Durvalumab 1,120 mg Q3W (to C15 or PD)
C1 C2 C3 C4 C5 C6
Fig. 1. Study schema. 
FACS, fluorescence-activated cell sorting; PD-L1, programmed death-ligand 1; Q3W, every 3 weeks.
1. Treatment arm
Neoadjuvant treatment: standard chemotherapy+durvalumab +tremelimumab.
Durvalumab: 1,500 mg every 3 weeks (Q3W; 3 total doses).
Tremelimumab: 75 mg Q3W (3 total doses).
Chemotherapy regimen: paclitaxel 175 mg/m2, carboplatin area under the curve (AUC) 5–6 
Q3W (3 total doses).
Adjuvant treatment: standard chemotherapy+durvalumab.
Durvalumab: 1,120 mg Q3W (12 total doses).
Chemotherapy regimen: paclitaxel 175 mg/m2, carboplatin AUC 5–6 Q3W (3 total doses).
Safety run-in phase
There will be a safety run-in phase with up to 7 patients. After that, a phase II expansion 
phase will be conducted with dosage levels considered safe.
Based on historical data, the proportion of patients who experience G3 or more treatment-
related adverse events (TRAEs) in the neoadjuvant chemotherapy will be approximately 
30%–50%, even without durvalumab and tremelimumab [8-10].
Enrollment will be suspended until after seven subjects have undergone surgery. Data and 
Safety Monitoring Board will review the safety of this trial and suggest recommendations, 
taking into consideration such examples as the following:
If patients who experience grade 3 or more TRAEs (except hematologic toxicity) are ≥4, 
then the trial will be stopped; If patients who experience grade 3 or more TRAEs (except 
hematologic toxicity) are ≤3, then the trial will proceed to phase II.
Any recommendations issued as a result of the above situations will be used to decide 
whether to stop the trial or proceed to phase II.
A single-arm phase II study
Durvalumab 1,500 mg IV, tremelimumab 75 mg IV, paclitaxel 175 mg/m2, and carboplatin 
AUC 5 or 6 will be administered every 3 weeks. Three cycles of neoadjuvant chemotherapy 
will be performed before interval debulking surgery. After surgery, durvalumab 1,120 mg IV, 
paclitaxel 175 mg/m2, and carboplatin AUC 5 or 6 will be administered every 3 weeks. Three 
cycles of adjuvant chemotherapy and 12 cycles of durvalumab will be performed after interval 
debulking surgery.
Treatment response assessments will be implemented every 3 cycles during the treatment 
period. For patients who achieve disease control after 12 months of treatment, tumor 
assessments should be performed relative to the date of first infusion as follows: every 12 
weeks for the first 2 years, then every 24 weeks thereafter until confirmed PD. All patients will 
be followed for at least 5 years after treatment is completed. Enhanced abdominal computed 
tomography and/or magnetic resonance imaging, chest computed tomography, and tumor 
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markers will be evaluated at least every 12 weeks until disease progression or death. Efficacy 
analyses are based on a modified intent-to-treat approach (patients should receive at least 
one treatment dose).
SAMPLE SIZE JUSTIFICATION
The sample size was calculated based on the 1-sample log-rank test.
Median PFS is 12 months in advanced-stage ovarian cancer from European Organisation 
for Research and Treatment of Cancer 55971 and Chemotherapy or Upfront Surgery. 
The rate of patients with disease-free status at 12 months is expected to be 50% with 
conventional chemotherapy (SOC). The rate of patients with disease-free status at 12 
months is expected to be 70% with the addition of immunotherapy (combination of 
durvalumab+tremelimumab+SOC followed by durvalumab+SOC) (hazard ratio=0.515). With 
80% statistical power and 5% of 1-sided type I errors, 21 patients are needed when patients 
are accrued for 12 months and followed for 30 months after the last patients is enrolled. The 
number of expected events would be 14. In anticipation of a 10% drop-out rate, 24 patients 
will be enrolled in this study.
MONITORING
The investigator or a designated representative must enter in the electronic case report form 
all information required by the protocol. The Data and Safety Monitoring Committee will 
review the results independently from the investigators and the study group statistician. The 
KGOG Data Center and study coordinator will conduct central monitoring and will issue a 
monitoring report every 6 months to evaluate study progress and improve data integrity and 
patient safety. For quality assurance, the KGOG Audit Committee will perform site audits. No 
interim analysis is planned for this study.
PARTICIPATING INSTITUTIONS
Yonsei University Severance Hospital, Seoul National University Hospital, Samsung Seoul 
Medical Center, National Cancer Center.
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